Nasdaq · Common stock
Braveheart Bio (BRVE)
$21.87 +$0.43 (+2.01%)
- Day’s range
- $21.10–$21.98
- Volume
- 101,221
BRVE price history
BRVE closed at $21.87 on Oct. 26, 2026. Over the past year, its daily close ranged from $18.58 on Oct. 7, 2026 to $30.00 on Aug. 7, 2026.
Data table: BRVE daily closes, the past year
| Date | Close |
|---|---|
| Oct. 26, 2026 | $21.87 |
| Oct. 23, 2026 | $21.44 |
| Oct. 22, 2026 | $21.48 |
| Oct. 21, 2026 | $21.04 |
| Oct. 20, 2026 | $20.27 |
| Oct. 19, 2026 | $19.21 |
| Oct. 16, 2026 | $18.71 |
| Oct. 15, 2026 | $19.55 |
| Oct. 14, 2026 | $19.34 |
| Oct. 13, 2026 | $19.33 |
| Oct. 12, 2026 | $20.36 |
| Oct. 9, 2026 | $20.02 |
| Oct. 8, 2026 | $19.09 |
| Oct. 7, 2026 | $18.58 |
| Oct. 6, 2026 | $19.79 |
| Oct. 5, 2026 | $21.35 |
| Oct. 2, 2026 | $21.27 |
| Oct. 1, 2026 | $21.41 |
| Sept. 30, 2026 | $20.20 |
| Sept. 29, 2026 | $22.34 |
| Sept. 28, 2026 | $21.07 |
| Sept. 25, 2026 | $20.62 |
| Sept. 24, 2026 | $23.37 |
| Sept. 23, 2026 | $21.46 |
| Sept. 22, 2026 | $23.61 |
| Sept. 21, 2026 | $25.02 |
| Sept. 18, 2026 | $29.20 |
| Sept. 17, 2026 | $27.71 |
| Sept. 16, 2026 | $27.45 |
| Sept. 15, 2026 | $26.71 |
| Sept. 14, 2026 | $27.02 |
| Sept. 11, 2026 | $26.64 |
| Sept. 10, 2026 | $27.25 |
| Sept. 9, 2026 | $28.91 |
| Sept. 8, 2026 | $29.41 |
| Sept. 4, 2026 | $26.74 |
| Sept. 3, 2026 | $26.27 |
| Sept. 2, 2026 | $26.95 |
| Sept. 1, 2026 | $26.28 |
| Aug. 31, 2026 | $25.50 |
| Aug. 28, 2026 | $27.44 |
| Aug. 27, 2026 | $27.86 |
| Aug. 26, 2026 | $27.76 |
| Aug. 25, 2026 | $27.64 |
| Aug. 24, 2026 | $27.50 |
| Aug. 21, 2026 | $27.58 |
| Aug. 20, 2026 | $27.42 |
| Aug. 19, 2026 | $28.97 |
| Aug. 18, 2026 | $26.75 |
| Aug. 17, 2026 | $27.66 |
| Aug. 14, 2026 | $27.03 |
| Aug. 13, 2026 | $25.97 |
| Aug. 12, 2026 | $26.15 |
| Aug. 11, 2026 | $25.01 |
| Aug. 10, 2026 | $27.53 |
| Aug. 7, 2026 | $30.00 |
| Aug. 6, 2026 | $29.80 |
Key figures
- Average daily volume
- 492,885Past 3 months
- Market value
- $1.97B
- Dividend yield
- —
Price change
- 1 month
- +6.06%
What Wall Street says about BRVE
In the past 90 days, Wall Street firms published 6 rating or price-target actions on BRVE: 5 new ratings and 1 reiterated rating.
| Action | Rating | |||
|---|---|---|---|---|
| Cantor Fitzgerald | Reiterates | Overweight | $40 | |
| Cantor Fitzgerald | Initiates coverage | Overweight | $40 | |
| Goldman Sachs | Initiates coverage | Buy | $48 | |
| Jefferies | Initiates coverage | Buy | $48 | |
| Stifel | Initiates coverage | Buy | $45 | |
| TD Cowen | Initiates coverage | Buy | — |
Ratings and price targets are the firms’ own opinions, reported as published.
Not investment advice.
About Braveheart Bio, Inc. Common Stock
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
- Headquarters
- San Francisco, Calif.
- Listed
- Aug. 6, 2026
- Sector
- Health care
- Industry
- Pharmaceutical preparations
In WallStreetDigest editions
No WallStreetDigest article about BRVE is on the site yet.